Nasonex partners up with American Forests to increase allergy awareness
KENILWORTH, N.J. Drug maker Schering-Plough, which recently agreed to an acquisition by Merck & Co., announced Wednesday that it would launch a campaign with a national tree-planting organization to educate consumers about nasal allergies and the environment.
Schering-Plough, which makes the prescription antihistamine nasal spray Nasonex (mometasone furoate monohydrate), has launched the “Don’t Blow It” Web site, at www.dontblowit.com, with American Forests. The drug maker described the site as an online health game with tips for people with nasal allergies and said that for each person who joins, it will donate money to plant a low-allergenic tree, for a total of up to 20,000.
Studies have indicated that higher levels of carbon dioxide in the atmosphere and warmer temperatures spur plant and pollen growth, resulting in earlier blooms and allergy seasons.
“I’ve noticed that my patients with seasonal nasal allergies are seeking treatment earlier each spring,” Easton, Pa.-based Valley Allergy & Asthma Center director Eric Schenkel said. “As many nasal allergy sufferers face longer seasons and more pollen, an online resource like the ‘Don’t Blow It’ game can help educate people about the importance of proper diagnosis and treatment, in an engaging and entertaining way.”
Study finds that Mannatech supplement can improve vision, memory
COPPELL, Texas One tablespoon of a dietary supplement can improve mental functioning, a study indicates.
The study, by researchers at Howard University and published in the journal Perceptual & Motor Skills, indicated that a tablespoon of Mannatech’s supplement Ambrotose can “significantly improve” visual discrimination and working memory.
“The results of this study are impressive because they show significant improvement in the perceptual capabilities of healthy adults, which indicates that Ambrotose complex can benefit everyone,” researcher Atiya Stancil said.
Stancil and fellow researcher Leslie Hicks conducted the randomized, double-blind, placebo-controlled study on 62 healthy young adults.
WellSpring’s anti-nausea medication proves successful in market
SARASOTA, Fla, WellSpring Pharmaceutical on Tuesday announced that its anti-nausea liquid Emetrol is now the leading product in its category based on trailing 52-week sales ended Jan. 14, citing data from Information Resources Inc.
Over that 52-week period, Emetrol marketshare grew to 51.7% of the category based on sales growth of more than 24%.
WellSpring recently rolled out a national advertising campaign targeting women between the ages of 25 and 34, the company stated. And the National Association of Pediatric Nurse Practitioners recently selected Emetrol for editorial content in an upcoming issue.
“The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by pediatricians for children under their care, has proven to be one of the most important attributes of the brand,” stated WellSpring president and CEO Robert Vukovich.